Literature DB >> 29152041

Selective Estrogen Receptor Degraders (SERDs): A Promising Treatment to Overcome Resistance to Endocrine Therapy in ERα-Positive Breast Cancer.

Ahmed F Abdel-Magid1.   

Abstract

Entities:  

Year:  2017        PMID： 29152041      PMCID： PMC5682615          DOI： 10.1021/acsmedchemlett.7b00424

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  4 in total

Review 1.  Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies.

Authors:  Weimin Fan; Jinjia Chang; Peifeng Fu
Journal:  Future Med Chem       Date:  2015-08-26       Impact factor: 3.808

2.  Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.

Authors:  Steven P Govek; Johnny Y Nagasawa; Karensa L Douglas; Andiliy G Lai; Mehmet Kahraman; Celine Bonnefous; Anna M Aparicio; Beatrice D Darimont; Katherine L Grillot; James D Joseph; Joshua A Kaufman; Kyoung-Jin Lee; Nhin Lu; Michael J Moon; Rene Y Prudente; John Sensintaffar; Peter J Rix; Jeffrey H Hager; Nicholas D Smith
Journal:  Bioorg Med Chem Lett       Date:  2015-10-03       Impact factor: 2.823

Review 3.  Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer.

Authors:  Shinji Ohno
Journal:  Clin Breast Cancer       Date:  2016-03-12       Impact factor: 3.225

Review 4.  A Review of Fulvestrant in Breast Cancer.

Authors:  Mark R Nathan; Peter Schmid
Journal:  Oncol Ther       Date:  2017-05-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.